Form 8-K - Current report:
SEC Accession No. 0001193125-25-241415
Filing Date
2025-10-16
Accepted
2025-10-16 16:10:20
Documents
13
Period of Report
2025-10-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d35488d8k.htm   iXBRL 8-K 25640
2 EX-99.1 d35488dex991.htm EX-99.1 15888
  Complete submission text file 0001193125-25-241415.txt   165427

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20251016.xsd EX-101.SCH 2843
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20251016_lab.xml EX-101.LAB 18736
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20251016_pre.xml EX-101.PRE 11702
15 EXTRACTED XBRL INSTANCE DOCUMENT d35488d8k_htm.xml XML 3767
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 251397729
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)